| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 7.0 | 6.8 | 5.5 |
| Other income | 0.2 | 2.0 | 0.0 |
| Total income | 7.1 | 8.8 | 5.5 |
| Profit before exceptional items & tax | -2.5 | -2.3 | -5.3 |
| Profit before tax | -2.5 | -2.3 | -5.3 |
| Net profit | -2.5 | -2.3 | -5.3 |
| Operating margin | -35.2% | -26.1% | -96.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +27.30% |
|---|---|
| Operating profit, year on year | +49.10% |
| Operating profit, quarter on quarter | +37.20% |
BSE results filing, NSE: KREBSBIO. Figures extracted from the filing.
Krebs Biochemicals & Industries Ltd: key numbers
- Share price
- ₹59.90
- Market cap
- ₹129.2 Cr
- Revenue (annual)
- ₹23.73 Cr
- Net profit (annual)
- ₹-16.93 Cr
- P/E (TTM)
- -9.2×Sector 47.4×
- Promoter holding
- 72.74%+0.00% QoQ
- FII holding
- 0.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krebs Biochemicals & Industries Ltd
All →Krebs Biochemicals & Industries Annual General Meeting
Krebs Biochemicals and Industries Limited has issued a notice for its 34th Annual General Meeting scheduled for September 29, 2026. Key agenda items include the approval of financial statements and related party transactions.
Krebs Biochemicals & Industries Annual Report
Krebs Biochemicals & Industries Limited has submitted its 34th Annual Report for the financial year 2025-26. The report includes financial highlights, directors' report, and audited financial statements.
Krebs Biochemicals & Industries Board Meeting Date
Krebs Biochemicals & Industries has scheduled a board meeting for August 6, 2026. The board will consider and adopt the unaudited Q1 results for June 30, 2026.
Krebs Biochemicals & Industries Legal & Regulatory
Krebs Biochemicals and Industries Ltd filed its shareholding pattern for June 2026, detailing promoter, institutional and other holdings. 20,400 promoter shares are in court dispute and remain undematerialised.
Krebs Biochemicals & Industries Merger & Restructuring
Krebs Biochemicals approved a merger with Ipca Laboratories Limited. The amalgamation aims for operational synergies and business consolidation.
Krebs Biochemicals & Industries Other Announcement
Krebs Biochemicals submitted its Annual Secretarial Compliance Report for the financial year ended March 2026. The report details governance compliance and historical penalties for board composition.